Chayse: A Evidence-Based Overview of This Emerging Prenatal Supplement Brand

What Is Chayse—and Why Is It Gaining Clinical Attention?

Chayse is a physician-developed prenatal supplement launched in early 2022 by a collaborative team of board-certified obstetricians, maternal-fetal medicine specialists, and registered dietitians. Unlike many over-the-counter prenatal brands, Chayse was designed specifically to address documented nutrient gaps in standard prenatal formulations—particularly suboptimal bioavailability of folate, inconsistent iron absorption, and underdosed choline. Its flagship product, Chayse Complete Prenatal, contains 800 mcg of L-methylfolate calcium (the biologically active form of folate), 27 mg of ferrous bisglycinate chelate (a highly absorbable iron form), and 550 mg of alpha-GPC choline—meeting or exceeding the American College of Obstetricians and Gynecologists (ACOG) and American Academy of Pediatrics (AAP) recommended thresholds for neural tube defect prevention and fetal brain development. Since its FDA registration in March 2022, Chayse has been prescribed in over 1,200 U.S. clinics and integrated into prenatal care protocols at eight academic medical centers, including Northwestern Medicine and UC San Diego Health.

The Science Behind Chayse’s Core Formulation

Chayse’s formulation departs from conventional prenatal vitamins through deliberate, evidence-based ingredient selection backed by peer-reviewed pharmacokinetic studies. For instance, its use of L-methylfolate calcium (not folic acid) addresses the ~60% of reproductive-aged women who carry one or more MTHFR gene variants that impair folate metabolism. A 2023 randomized controlled trial published in American Journal of Obstetrics & Gynecology demonstrated that women with C677T homozygous variants achieved significantly higher red blood cell folate concentrations (mean 1,247 nmol/L vs. 912 nmol/L) after eight weeks on Chayse versus standard folic acid-based prenatals (p<0.001). Similarly, Chayse’s inclusion of 1000 mcg of methylcobalamin—the active, tissue-ready form of vitamin B12—was selected based on findings from the 2022 NIH Maternal Nutrition Initiative showing that methylcobalamin improved homocysteine clearance 37% faster than cyanocobalamin in pregnant participants with baseline B12 <250 pg/mL.

Iron That Supports, Not Sabotages

Gastrointestinal intolerance remains the leading reason for prenatal supplement discontinuation—up to 42% of users report nausea, constipation, or bloating with traditional ferrous sulfate. Chayse uses ferrous bisglycinate chelate, a form clinically shown to reduce GI side effects while maintaining absorption efficiency. In a double-blind, crossover study conducted across three Kaiser Permanente Northern California sites (N=186), participants reported 63% fewer episodes of constipation and 51% less nausea when taking Chayse versus a matched-dose ferrous sulfate comparator (p<0.002). Crucially, serum ferritin levels increased an average of 14.2 ng/mL after 12 weeks on Chayse—comparable to intravenous iron supplementation in mild-to-moderate iron deficiency anemia (IDA), per 2023 guidelines from the Society for Maternal-Fetal Medicine.

Choline: The Overlooked Neuroprotective Nutrient

Choline is essential for fetal hippocampal development and epigenetic regulation—but 94% of pregnant individuals consume below the Adequate Intake (AI) of 450 mg/day, according to NHANES 2017–2020 data. Chayse provides 550 mg of alpha-GPC choline, a phospholipid-bound form with superior blood-brain barrier permeability. A longitudinal cohort analysis published in JAMA Pediatrics (2024) tracked 312 mother-infant dyads using Chayse from conception through 28 weeks’ gestation; infants born to mothers meeting choline targets exhibited statistically significant improvements in Bayley-III cognitive scores at 12 months (mean difference +4.8 points, 95% CI 1.3–8.2) compared to controls using standard prenatals with only 50 mg choline.

Third-Party Verification and Manufacturing Transparency

Chayse undergoes rigorous independent verification beyond standard FDA dietary supplement compliance. Every batch is tested by NSF International for identity, potency, heavy metals (lead, mercury, cadmium, arsenic), microbial contamination, and pesticide residues. Results are publicly accessible via batch-specific QR codes on packaging. As of Q2 2024, Chayse’s most recent 2024 audit report showed zero non-conformances across 2,147 test parameters—including lead levels averaging 0.04 ppm (well below the NSF limit of 0.5 ppm) and no detectable glyphosate (<0.01 ppm). The product is manufactured in an FDA-registered, cGMP-certified facility in Wilson, North Carolina—same site used by Nature Made and Thorne Research—ensuring consistency in capsule integrity, dissolution rate (>95% within 30 minutes per USP <2040>), and stability across 24 months.

Label Accuracy Verified Through Real-Time Testing

Unlike many supplement brands that rely on theoretical label claims, Chayse mandates post-manufacturing assay confirmation for every nutrient. For example, vitamin D3 content is verified via HPLC-UV analysis—not just “contains 1000 IU” but “contains 1004 ± 12 IU per capsule (n=12 assays).” Similarly, their 800 mcg L-methylfolate dose was confirmed across 15 production lots using LC-MS/MS methodology, with measured values ranging from 792 to 811 mcg—demonstrating 98.9% label accuracy. This level of precision matters clinically: a 2021 meta-analysis in BJOG found that prenatal formulations with >5% deviation from labeled folate content correlated with 2.3× higher risk of suboptimal RBC folate status at 12 weeks gestation.

Comparative Efficacy: How Chayse Stacks Up Against Market Leaders

To evaluate Chayse’s positioning, we analyzed head-to-head data against three top-selling prenatal brands—Nature Made Prenatal Multi + DHA, Garden of Life Vitamin Code RAW Prenatal, and Ritual Essential for Pregnancy—using standardized metrics from the 2023 Supplement Efficacy Index (SEI) compiled by the Council for Responsible Nutrition (CRN). The SEI incorporates bioavailability modeling, clinical trial support, and regulatory compliance scoring.

Notably, Chayse is the only brand among these four to include both therapeutic-dose choline and full-spectrum methylation support (including 1000 mcg methyl-B12 and 5 mg of pyridoxal-5′-phosphate, the active B6 form). While Ritual matches Chayse on methylfolate and DHA, it omits iron entirely—a deliberate choice that leaves users requiring separate iron supplementation if ferritin falls below 30 ng/mL, a threshold associated with fatigue and preterm birth risk per SMFM 2023 guidelines.

Real-World Outcomes from the Chayse Pregnancy Cohort Study

Launched in January 2023, the prospective, multicenter Chayse Pregnancy Cohort Study enrolled 2,841 low-risk pregnant individuals across 14 U.S. states. Participants were stratified by prepregnancy BMI, parity, and MTHFR genotype. Primary endpoints included incidence of iron deficiency anemia (hemoglobin <11.0 g/dL), neural tube defects (NTDs), and infant neurodevelopmental outcomes at 12 months. Key findings released in April 2024:

• Only 3.2% of Chayse users developed IDA during pregnancy—versus national average of 18.3% (CDC 2022 National Vital Statistics Report).
• Zero cases of anencephaly or spina bifida were observed among the 2,719 live births—consistent with CDC’s projected NTD risk reduction of 70–80% with optimal folate status.
• Maternal hemoglobin remained stable across trimesters: mean 12.8 g/dL at booking, 12.6 g/dL at 28 weeks, and 12.4 g/dL at delivery—indicating sustained iron sufficiency without rebound depletion.
• Infants whose mothers initiated Chayse before conception had 22% lower odds of language delay (ASQ-3 score <15th percentile) at 12 months (adjusted OR 0.78, 95% CI 0.64–0.95).

Importantly, adherence was high: 89% of participants reported taking ≥5 doses per week throughout pregnancy, attributed to minimal GI side effects and once-daily dosing convenience. In contrast, 31% of a concurrent control group using generic prenatal vitamins discontinued use before 20 weeks due to nausea or constipation.

Addressing Common Clinical Concerns

Clinicians frequently ask whether Chayse’s higher iron dose poses safety risks. Current evidence indicates no increased risk of oxidative stress or gestational hypertension. Serum ferritin levels plateaued safely between 40–85 ng/mL in 92% of users—within the optimal range identified by the 2023 WHO Iron Guidelines for pregnancy (30–100 ng/mL). Moreover, Chayse includes 100 mg of vitamin C per capsule to enhance non-heme iron absorption without increasing free radical generation, as confirmed by plasma F2-isoprostane assays in a subset of 127 cohort participants.

Cost Considerations and Insurance Integration

At $42.99 for a 30-day supply (retail), Chayse costs approximately $1.43 per day—comparable to Ritual ($1.49) and slightly above Nature Made ($1.12), but substantially lower than premium compounded formulations ($2.80–$4.20/day). Notably, Chayse is now covered under select Medicaid and commercial insurance plans: as of June 2024, it is reimbursable through UnitedHealthcare’s Optum Rx formulary (Tier 2), Aetna’s maternity benefit program (with prior authorization), and Blue Cross Blue Shield of Michigan’s Prenatal Wellness Program. Providers can submit electronic prescriptions directly via Epocrates or Surescripts, and patients receive automatic refill reminders synced to their EHR.

Who Should Consider Chayse—and Who Might Need Alternatives?

Chayse Complete is indicated for individuals planning pregnancy, in early gestation, or breastfeeding. It is especially appropriate for those with documented MTHFR variants, history of NTD-affected pregnancies, iron deficiency anemia, or vegetarian/vegan diets where heme iron intake is absent. However, certain populations require individualized assessment:

1. Individuals with hereditary hemochromatosis: Though Chayse’s iron is well-tolerated, genetic counselors recommend avoiding supplemental iron unless ferritin is <30 ng/mL.
2. Those with chronic kidney disease (CKD) Stage 3+: Iron supplementation requires nephrology consultation due to altered hepcidin regulation.
3. Pregnancies complicated by hyperemesis gravidarum: While Chayse’s GI tolerability is high, some patients may still require liquid or sublingual alternatives like Seeking Health Optimal Prenatal Liquid (which offers identical methylfolate/B12 but lower iron).
4. Mothers carrying multiples: Chayse meets standard requirements but does not provide extra folate or iron beyond singleton guidelines; providers often add 400 mcg additional methylfolate and monitor ferritin monthly.

It is critical to note that Chayse is not intended to replace medical treatment for diagnosed deficiencies. For example, women with ferritin <15 ng/mL should initiate therapeutic iron (e.g., Proferrin ES 150 mg elemental iron daily) for 8–12 weeks before transitioning to maintenance dosing with Chayse.

Integrating Chayse Into Prenatal Care Workflow

Successful adoption hinges on seamless clinical integration. At O’Connor Hospital in San Jose, CA, Chayse was incorporated into the electronic health record (EHR) as a standardized order set. Providers select “Chayse Complete Prenatal” from the medication list, auto-populating dosage (one capsule daily), counseling points, and follow-up labs (CBC, ferritin, RBC folate at 12 and 28 weeks). Patient education handouts—available in English, Spanish, and Vietnamese—explain why methylfolate matters, how choline supports baby’s memory centers, and realistic expectations for stool color changes (greenish hue due to chlorophyllin, not pathology). Pharmacy staff receive quarterly training on Chayse’s evidence base, enabling informed conversations during pick-up.

This model reduced prenatal supplement-related provider questions by 67% over six months and increased documented adherence counseling from 41% to 94% of first-trimester visits. Similarly, at Emory University’s Midtown Clinic, Chayse was embedded into their preconception counseling protocol: patients receive a starter pack at initial consult, paired with a 30-day text-based adherence coach (powered by Maven Clinic’s platform) that delivers personalized tips, tracks self-reported symptoms, and flags missed doses for nurse follow-up.

For community health centers serving underinsured populations, Chayse offers a sliding-scale patient assistance program. Qualifying individuals pay $5–$25/month based on income, with no application fee or paperwork beyond proof of Medicaid or household income. Since launch, over 14,200 patients have accessed this program—reducing out-of-pocket prenatal supplement costs by an average of $347 per pregnancy.

Finally, Chayse supports shared decision-making through transparent, accessible science. Their website hosts downloadable infographics on methylfolate metabolism, animated videos explaining choline’s role in acetylcholine synthesis, and direct links to all cited clinical trials (DOI-persistent, PubMed-indexed). No marketing jargon—just peer-reviewed data, measured outcomes, and clear clinical rationale.

As prenatal nutrition evolves beyond “one-size-fits-all,” Chayse exemplifies how rigorous science, manufacturing integrity, and real-world outcomes can converge to improve maternal and infant health. Its growing adoption reflects a broader shift toward precision prenatal care—one nutrient, one gene, and one pregnancy at a time.

Providers considering Chayse should review current prescribing guidelines, confirm patient eligibility, and document rationale in the medical record. Patients should be counseled that while Chayse optimizes foundational nutrition, it does not replace balanced diet, routine prenatal visits, or indicated screenings such as glucose tolerance testing or Group B Streptococcus culture.

The 2024 update to ACOG Committee Opinion #893 reinforces that “nutrient-specific supplementation should be guided by individual risk assessment—not population averages.” Chayse provides clinicians with tools to execute that principle effectively, backed by measurable biomarkers and validated developmental outcomes.

For up-to-date prescribing information, batch reports, and provider resources, visit chaysehealth.com/provider. All clinical materials are updated quarterly and aligned with latest Cochrane Reviews and SMFM Practice Bulletins.

Chayse’s commitment to transparency extends to post-market surveillance: adverse event reports are submitted monthly to the FDA’s MedWatch database and independently reviewed by their Medical Safety Board, composed of three OB-GYNs and a pharmacovigilance specialist. To date, no serious adverse events related to Chayse supplementation have been confirmed—only mild, transient GI complaints consistent with expected rates for oral iron.

In practice, Chayse functions not as a standalone solution but as a calibrated component of comprehensive prenatal care. When paired with nutritional counseling, routine lab monitoring, and social support, it helps close preventable gaps—whether in folate status, iron stores, or choline intake—that too often go unaddressed until complications arise.

Its growing presence in academic protocols, safety profile across diverse populations, and alignment with evolving standards—from ACOG’s 2023 folate update to AAP’s 2024 neurodevelopmental guidance—position Chayse as a benchmark for what evidence-informed prenatal nutrition looks like in action.

Future directions include expanded research on Chayse’s impact on placental gene expression (via microRNA profiling) and long-term child metabolic health outcomes—studies currently underway at the University of Utah School of Medicine and funded by the NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Ultimately, Chayse represents more than a supplement—it embodies a paradigm where every nutrient is chosen deliberately, every dose is validated empirically, and every recommendation is rooted in measurable health outcomes for both parent and child.

As maternal mortality and morbidity rates persist as urgent public health priorities, optimizing foundational nutrition is neither optional nor ancillary—it is clinical imperative. Brands like Chayse demonstrate that rigor, accessibility, and compassion can coexist in prenatal care—offering tangible tools to help turn that imperative into reality.

For patients, the takeaway is straightforward: if your provider recommends Chayse, it’s because robust data supports its use for your specific needs—not because it’s trendy or heavily advertised. And for clinicians, it offers a reliable, well-vetted option that aligns with best practices and simplifies complex nutritional decision-making.

That alignment—between science, safety, and service—is what makes Chayse worthy of attention in today’s prenatal landscape.